Matches in SemOpenAlex for { <https://semopenalex.org/work/W2619158663> ?p ?o ?g. }
Showing items 1 to 96 of
96
with 100 items per page.
- W2619158663 abstract "Abstract Despite receiving Rituximab-combined chemotherapy, approximately half of follicular lymphoma (FL) patients suffer tumor recurrence, a major clinical issue. Retrieval of lymphoma stem-like cells from these poorly understood, intractable lymphomas would thus greatly ameliorate the cancer therapeutics. Here we demonstrate that the TRA-1-60-expressing cells are a unique population in FLs, converge to the conventional stem cell marker Oct3/4 and ALDH1-positive population, and strongly resist current agents against B-cell lymphomas. TRA-1-60 expression was detected in minor populations of resting B-lymphocytes inside germinal centers in reactive lymphoid tissue, whereas scattered TRA-1-60-expressing cells were detected in the marginal area of neoplastic follicles of FLs, close to small blood vessels. Translocation t(14;18) was thus detected in DNAs from the TRA-positive cells in all five patients' samples, which evinced the identical pattern of gene fusion as that of TRA-negative cells in the same tissue in 4 of 5 fresh frozen FL samples. Retrospective histological comparison between the recurrent and cognate primary tissues revealed that the number of TRA-1-60-positive lymphoma cells from R-CHOP treated FL subjects had increased four-fold relative to primary tissue, a finding corroborated by in vitro assay on Rituximab treated 2 cell lines, wherein TRA-positive cell numbers increased over ten to thirty-fold compared to the untreated sample. Moreover, TRA-1-60-positive cell population was markedly resistant to current therapeutic agents for B-cell lymphomas. Concordantly, small numbers of TRA-1-60-positive cells implanted subcutaneously into NOD/SCID mice evinced potent tumor-initiating capacity in vivo, where tumors were twelve-fold larger in volume (p=0.0021<0.005) and thirteen-fold heavier in weight (p=0.0015<0.005) compared to those xenografted from the TRA-negative cells. In conclusion, while further investigation for molecular insights will be necessary, it is now clear that TRA-1-60 should be a prominent focus among cellular markers in follicular lymphoma research, by which we ultimately hope to explain clinical intractability against combination-Rituximab and other therapies, and to better understand the stemness among a range of lymphoma cell types. Disclosures Maeda: Mundipharma KK: Research Funding." @default.
- W2619158663 created "2017-06-05" @default.
- W2619158663 creator A5011042700 @default.
- W2619158663 creator A5025889209 @default.
- W2619158663 creator A5034020706 @default.
- W2619158663 creator A5034249454 @default.
- W2619158663 creator A5037266475 @default.
- W2619158663 creator A5048030695 @default.
- W2619158663 creator A5066275550 @default.
- W2619158663 creator A5074447395 @default.
- W2619158663 creator A5076142771 @default.
- W2619158663 date "2016-12-02" @default.
- W2619158663 modified "2023-09-29" @default.
- W2619158663 title "Identification of TRA-1-60-Positive Cells As a Potent Refractory Population in Follicular Lymphomas" @default.
- W2619158663 doi "https://doi.org/10.1182/blood.v128.22.4122.4122" @default.
- W2619158663 hasPublicationYear "2016" @default.
- W2619158663 type Work @default.
- W2619158663 sameAs 2619158663 @default.
- W2619158663 citedByCount "0" @default.
- W2619158663 crossrefType "journal-article" @default.
- W2619158663 hasAuthorship W2619158663A5011042700 @default.
- W2619158663 hasAuthorship W2619158663A5025889209 @default.
- W2619158663 hasAuthorship W2619158663A5034020706 @default.
- W2619158663 hasAuthorship W2619158663A5034249454 @default.
- W2619158663 hasAuthorship W2619158663A5037266475 @default.
- W2619158663 hasAuthorship W2619158663A5048030695 @default.
- W2619158663 hasAuthorship W2619158663A5066275550 @default.
- W2619158663 hasAuthorship W2619158663A5074447395 @default.
- W2619158663 hasAuthorship W2619158663A5076142771 @default.
- W2619158663 hasBestOaLocation W26191586632 @default.
- W2619158663 hasConcept C142724271 @default.
- W2619158663 hasConcept C147483822 @default.
- W2619158663 hasConcept C153911025 @default.
- W2619158663 hasConcept C159654299 @default.
- W2619158663 hasConcept C196166836 @default.
- W2619158663 hasConcept C203014093 @default.
- W2619158663 hasConcept C2777058707 @default.
- W2619158663 hasConcept C2778453870 @default.
- W2619158663 hasConcept C2779338263 @default.
- W2619158663 hasConcept C2779725641 @default.
- W2619158663 hasConcept C2780653079 @default.
- W2619158663 hasConcept C28328180 @default.
- W2619158663 hasConcept C2908647359 @default.
- W2619158663 hasConcept C502942594 @default.
- W2619158663 hasConcept C54355233 @default.
- W2619158663 hasConcept C71924100 @default.
- W2619158663 hasConcept C86803240 @default.
- W2619158663 hasConcept C96926380 @default.
- W2619158663 hasConcept C99454951 @default.
- W2619158663 hasConceptScore W2619158663C142724271 @default.
- W2619158663 hasConceptScore W2619158663C147483822 @default.
- W2619158663 hasConceptScore W2619158663C153911025 @default.
- W2619158663 hasConceptScore W2619158663C159654299 @default.
- W2619158663 hasConceptScore W2619158663C196166836 @default.
- W2619158663 hasConceptScore W2619158663C203014093 @default.
- W2619158663 hasConceptScore W2619158663C2777058707 @default.
- W2619158663 hasConceptScore W2619158663C2778453870 @default.
- W2619158663 hasConceptScore W2619158663C2779338263 @default.
- W2619158663 hasConceptScore W2619158663C2779725641 @default.
- W2619158663 hasConceptScore W2619158663C2780653079 @default.
- W2619158663 hasConceptScore W2619158663C28328180 @default.
- W2619158663 hasConceptScore W2619158663C2908647359 @default.
- W2619158663 hasConceptScore W2619158663C502942594 @default.
- W2619158663 hasConceptScore W2619158663C54355233 @default.
- W2619158663 hasConceptScore W2619158663C71924100 @default.
- W2619158663 hasConceptScore W2619158663C86803240 @default.
- W2619158663 hasConceptScore W2619158663C96926380 @default.
- W2619158663 hasConceptScore W2619158663C99454951 @default.
- W2619158663 hasLocation W26191586631 @default.
- W2619158663 hasLocation W26191586632 @default.
- W2619158663 hasOpenAccess W2619158663 @default.
- W2619158663 hasPrimaryLocation W26191586631 @default.
- W2619158663 hasRelatedWork W1580176919 @default.
- W2619158663 hasRelatedWork W1634431533 @default.
- W2619158663 hasRelatedWork W1975510611 @default.
- W2619158663 hasRelatedWork W2062186653 @default.
- W2619158663 hasRelatedWork W2128378497 @default.
- W2619158663 hasRelatedWork W2325487268 @default.
- W2619158663 hasRelatedWork W2334650409 @default.
- W2619158663 hasRelatedWork W2397148027 @default.
- W2619158663 hasRelatedWork W2474143426 @default.
- W2619158663 hasRelatedWork W2559915999 @default.
- W2619158663 hasRelatedWork W2566210609 @default.
- W2619158663 hasRelatedWork W2586893193 @default.
- W2619158663 hasRelatedWork W2883174416 @default.
- W2619158663 hasRelatedWork W2929570224 @default.
- W2619158663 hasRelatedWork W2978143802 @default.
- W2619158663 hasRelatedWork W2980209846 @default.
- W2619158663 hasRelatedWork W2988747044 @default.
- W2619158663 hasRelatedWork W3012010773 @default.
- W2619158663 hasRelatedWork W91236835 @default.
- W2619158663 hasRelatedWork W144642353 @default.
- W2619158663 isParatext "false" @default.
- W2619158663 isRetracted "false" @default.
- W2619158663 magId "2619158663" @default.
- W2619158663 workType "article" @default.